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PMH16
ATYPICAL ANTIPSYCHOTICS IN THE 
TREATMENT OF SCHIZOPHRENIA: ADVERSE 
EVENTS, NON-COMPLIANCE AND COST
Meddis D1, Williams P2
1AstraZeneca, Macclesfield, Cheshire, UK; 2PAREXEL Medical 
Marketing Services, Uxbridge, UK
OBJECTIVE: to estimate the economic impact of non-
compliance associated with two adverse events (weight
change, extrapyramidal symptoms [EPS]) resulting from
treatment of schizophrenia with atypical antipsychotics.
METHODS: Differential adverse event profiles were ex-
pected to cause differences between antipsychotics in
terms of compliance, relapse rate and direct costs. Using
a state-transition model, non-compliance and relapse
over one year following recovery from a schizophrenic
episode were simulated. Three transition probabilities
governed movement between states: WELL, COMPLI-
ANT to RELAPSE, derived from literature on relapse with
atypical antipsychotics; WELL, NON-COMPLIANT to
RELAPSE, derived from a quantitative literature summary
of relapse following antipsychotic withdrawal; WELL,
COMPLIANT to WELL, NON-COMPLIANT, based on
non-compliance estimates from a two-round Delphi study.
Twenty-five experts in the treatment of schizophrenia,
blind to the identity of the products, reviewed published
literature on weight change and EPS liability for olanza-
pine, quetiapine, risperidone and ziprasidone. Respon-
dents assumed them to be identical except for adverse
event liability. Bootstrap estimates of differential relapse
rates between the atypicals were obtained, accounting
for uncertainty in all three transition probabilities. Pub-
lished data on direct costs of relapse were applied, giving
incremental cost estimates for different adverse event lia-
bilities.
RESULTS: Quetiapine and ziprasidone were similar in
estimated non-compliance and relapse rates. Compared
to quetiapine, greater weight change with olanzapine led
to higher estimated non-compliance and incremental one-
year per-patient costs of $530 (95% CI  $275–800,
p  .00001), using USA-based cost data. Greater EPS lia-
bility with risperidone led to higher estimated non-com-
pliance and incremental one-year per-patient costs of
$485 (95% CI  $235–800, p  .00001) compared to
quetiapine. Similar increased costs of treatment with
olanzapine and risperidone were shown (£630 [95% CI 
£330-960] and £575 [95% CI  £280–960] respectively)
when UK-based cost data were used.
CONCLUSIONS: The more favourable adverse event
profile of quetiapine is associated with a predicted de-
crease in one-year per-patient direct costs compared to
olanzapine and risperidone.
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LONG-TERM ECONOMIC BENEFITS OF 
ANTIPSYCHOTIC USE
Boscoe AN1, White RE1, Bolge SC2
1AstraZeneca, Wilmington, DE, USA; 2Consumer Health 
Sciences, Princeton, NJ, USA
OBJECTIVES: To illustrate the decrease in resource utili-
zation over time among persons with bipolar disorder
treated with antipsychotics.
METHODS: In December 2000, 234 persons reported a
diagnosis of bipolar disorder on a self-administered ques-
tionnaire. Of these, 57 reported currently using an anti-
psychotic: Haldol, Risperdal, Seroquel, and Zyprexa. Re-
spondents using antipsychotics were categorized according
to the number of months on drug: zero to six, and seven or
greater. The treatment-duration groups were compared by
resource use during a six-month period: number of visits
to all outpatient providers, including primary physician,
counselor, gynecologist, neurologist, psychiatrist, psychol-
ogist, and other medical specialists; visits to the emergency
room for mental health reasons; days hospitalized for men-
tal health reasons. Lastly, costs of resources used were cal-
culated based on US Census Bureau, Statistical Abstracts
of the United States, 2000: emergency room costs, $320
per visit; hospitalizations, $1,126 per day; outpatient pro-
vider costs, $85 per visit.
RESULTS: Respondents using antipsychotics for seven
months or longer had fewer visits to outpatient providers
(17.1 versus 30.9, p  0.086), emergency room visits (0.2
versus 0.7, p  0.062) and days of hospitalization (1.6
versus 3.8, p  0.202) than those using an antipsychotic
for six months or less. Among respondents using an an-
tipsychotic for seven months or longer, the average cost
of outpatient resource use ($1453.23 versus $2623.91),
ER visits for mental health reasons ($70.00 versus
$208.70), and hospitalization for mental health reasons
($1816.13 versus $4299.27) are lower than among those
using an antipsychotic for six months or less.
CONCLUSION: Resource utilization, especially hospital-
ization, during the early months of antipsychotic use is
very costly. However, continued use of antipsychotics
leads to a decrease in inpatient and outpatient resource uti-
lization. Therefore, it becomes more cost-effective to main-
tain a patient on antipsychotic medication over time.
PMH18
DEPRESSION AND QUALITY OF LIFE AND 
THEIR EFFECT ON HEALTH-CARE UTILIZATION
Bushnell DM, Martin ML
Health Research Associates Inc (HRA), Seattle, WA
OBJECTIVE: To describe use of health-care resources by
levels of depression and quality of life (QOL).
METHODS: The Longitudinal Investigation of Depres-
sion Outcomes (LIDO) is an observational study measur-
ing depression and its economic and QOL correlates in
patients visiting primary care clinics in six international
cities (Barcelona, Be’er Sheva, Melbourne, Porto Alegre,
St. Petersburg, and Seattle). Health-care utilization was
assessed using an interview-based resource utilization
questionnaire (RUQ) collecting information on the type,
